New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
10:00 EDTHAFC, SALE, BTU, MRK, EIX, AGI, KSU, FMBI, PB, MHK, MTG, ETFC, SMI, XOOM, POT, MTH, HON, ATLSOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alamos Gold (AGI) upgraded to Outperform from Sector Perform at RBC Capital... Atlas Energy (ATLS) upgraded to Outperform from Neutral at RW Baird... E-Trade (ETFC) upgraded to Outperform from Market Perform at JMP Securities... Edison International (EIX) upgraded to Hold from Underperform at Jefferies... Honeywell (HON) upgraded to Buy from Hold at Lagenberg... MGIC Investment (MTG) upgraded to Outperform from Market Perform at JMP Securities... Merck (MRK) upgraded to Overweight from Underweight at Morgan Stanley... Meritage Homes (MTH) upgraded to Overweight from Equal Weight at Barclays... Mohawk (MHK) upgraded to Overweight from Neutral at JPMorgan... Peabody (BTU) upgraded to Neutral from Underperform at BofA/Merrill... Potash (POT) upgraded to Outperform from Market Perform at Raymond James... Prosperity Bancshares (PB) upgraded to Outperform from Market Perform at BMO Capital... RetailMeNot (SALE) upgraded to Buy from Neutral at Goldman... Xoom (XOOM) upgraded to Strong Buy from Market Perform at Raymond James... First Midwest (FMBI) upgraded to Outperform from Market Perform at Fig Partners... Hanmi Financial (HAFC) upgraded to Outperform from Market Perform at Keefe Bruyette... Semiconductor Manufacturing (SMI) upgraded to Buy from Sell at UBS... Kansas City Southern (KSU) upgraded to Neutral from Underperform at Buckingham.
News For AGI;ATLS;ETFC;EIX;HON;MTG;MRK;MTH;MHK;BTU;POT;PB;SALE;XOOM;FMBI;HAFC;SMI;KSU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 22, 2015
10:52 EDTMRKJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
07:22 EDTMRKMerck receives positive CHMP opinion for Pembrolizumab in advanced melanoma
Subscribe for More Information
07:15 EDTMRKMerck receives positive CHMP opinion for KEYTRUDA in advanced melanoma
Merck announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma, as both first-line therapy and in previously treated patients. The CHMP positive opinion for KEYTRUDA, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the European Union.
May 21, 2015
07:14 EDTPOTBMO Capital to hold a conference
Subscribe for More Information
May 19, 2015
09:58 EDTPOTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Ascena Retail (ASNA) upgraded to Outperform from Market Perform at FBR Capital... Enphase Energy (ENPH) upgraded to Strong Buy from Buy at Needham... Fifth Third (FITB) upgraded on Vantiv outlook at Oppenheimer... Hortonworks (HDP) upgraded to Overweight from Equal Weight at Barclays... MasterCard (MA) upgraded to Overweight from Sector Weight at Pacific Crest... NetEase.com (NTES) upgraded to Buy from Neutral at Citigroup... Panera Bread (PNRA) upgraded to Outperform from Market Perform at Cowen... Potash (POT) upgraded to Market Perform from Underperform at Cowen... Reed Elsevier (RUK) upgraded to Buy from Neutral at Goldman... Royal Caribbean (RCL) upgraded to Overweight from Neutral at JPMorgan... Sysco (SYY) upgraded at Credit Suisse... THL Credit (TCRD) upgraded to Buy from Hold at Deutsche Bank... Take-Two (TTWO) upgraded to Buy from Neutral at Sterne Agee CRT... Tempur Sealy (TPX) upgraded on Sealy gross margin improvement at Longbow... TriState Capital (TSC) upgraded to Outperform from Market Perform at Keefe Bruyette... Xilinx (XLNX) upgraded to Overweight from Sector Weight at Pacific Crest.
07:42 EDTPOTPotash upgraded to Market Perform from Underperform at Cowen
Subscribe for More Information
07:34 EDTMTHJPMorgan to hold a conference
Subscribe for More Information
07:28 EDTMRKUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:55 EDTMRKGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
16:21 EDTATLSAtlas Resource Partners to acquire Arkoma assets from Atlas Energy for $35.5M
Subscribe for More Information
10:01 EDTKSUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTHONHoneywell provides 2018 core organic growth targets
Subscribe for More Information
09:57 EDTHONHoneywell repeats FY15 EPS view $6.00-$6.15, consensus $6.09
Repeats FY15 revenue view $39B-$39.6B, consensus $39.39B. Sees FY15 segment margin up 170-200bps, sees FY15 free cash flow $4.2B-$4.3B. Sees 2H core organic sales acceleration. Says "confident" in 2015 outlook. Says busineses well positioned to grow.
09:55 EDTHONHoneywell sees Q2 EPS $1.56-$1.51, consensus $1.49
Subscribe for More Information
09:49 EDTHONEquity options with increasing volume
Subscribe for More Information
09:36 EDTBTUActive equity options trading on open
Subscribe for More Information
07:56 EDTKSUKansas City Southern downgraded due to lower volumes at BofA/Merrill
As previously reported, BofA/Merrill downgraded Kansas City Southern to Neutral from Buy and lowered its price target to $97 from $116. The firm said Kansas City Southern already pulled guidance and Q2 carloads to date are down 7%, versus its 1% growth forecast and coal carloads are down 44%, below its forecast of down 7%, due to large customer. Luminent, being virtually shut-down due to low natural gas prices.
07:19 EDTHONElectric Products Group to hold a conference
EPG 2015 is being held in Longboat Key, Florida on May 18-20 with webcasted company presentations to begin on May 18 at 7:30 am; not all company presentations may be webcasted. Webcast Link
06:58 EDTHONHoneywell says M&A pipeline includes over 100 potential targets, Bloomberg says
Subscribe for More Information
06:47 EDTKSUKansas City Southern downgraded to Neutral from Buy at BofA/Merrill
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use